Masahide Oki

Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial

K. Imaizumi, H. Itani, Y. Kuwatsuka, 2023, EClinicalMedicine.

The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma

T. Ohira, Y. Miyata, M. Takeda, 2024, JTO clinical and research reports.

Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer

J. Tanizaki, K. Sakai, H. Hayashi, 2024, British Journal of Cancer.

NOTCH1 and CREBBP co‐mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR‐mutated NSCLC: translational research of phase III IMPACT study

Y. Ohde, H. Akamatsu, H. Tada, 2023, Molecular oncology.